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Introduction
Fc receptor signaling is an important process in the immunological response for macrophages, neurophils and mast cells (Turner, et al., 2000) . Activation of the Fc receptor results in the degranulation and gene transcription of cytokines that play a critical role in inflammation. Binding of ligands to the Fc receptor results in activation of intracellular immunoreceptor tyrosine-based activation motifs (ITAMS) that interact with the non receptor Spleen Tyrosine Kinase (Syk) for downstream signaling. Because of its critical role in the Fc receptor signal transduction, inhibition of Syk represents a potential target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and idiopathic thrombocytopenia purpura (ITP) (Wong, et al., 2004; Singh and Masuda, 2007) .
R406 is a small molecule that is a relatively selective Syk inhibitor and a potent inhibitor of IgE and IgG-mediated activation of Fc receptor signaling (Braselmann et al., 2006) . In a rodent collagen-induced arthritis model R406 was shown to produce significant improvement in histopathology, clinical scores, and joint radiography (Pine et al., 2007) . R406 exhibits low aqueous solubility, which limits the potential for solid dosage form development. Previous reports suggested that use of phosphate prodrugs can produce extensive improvement in bioavailability when compared with the parent compound (Vierling and Greiner, 2003; Furefine et al., 2004) . Therefore, the methylene phosphate prodrug of R406, R788 (fostamatinib), was synthesized and tested in preclinical and clinical studies. When tested in animals and in human volunteers, R788 in a simple suspension formulation resulted in systemic exposure of R406 that is comparable, or This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 6, 2010 as DOI: 10.1124/dmd.110.032151 at ASPET Journals on June 22, 2017 dmd.aspetjournals.org Downloaded from DMD #32151 6 better than R406 administration using a solution formulation. In RA patients, oral administration of R788 tablets resulted in R406 exposure that is sufficient to demonstrate significant improvement of ACR scores in two large clinical trials (Weinblatt et al., 2008 , Weinblatt et al., 2009 . R788 has also shown promise in the treatment of ITP (Podolanczuk et al., 2009) .
Little is known regarding the metabolism and disposition of R788 in humans. Therefore, in vitro studies using human liver and intestinal microsomes were conducted to evaluate the pathways of R788/R406 metabolism. In addition, a 14 C-radiolabelled mass balance study in healthy male subjects was performed in an effort to gain understanding of the metabolic pathways and disposition of the R788/R406 in humans. The findings from these studies are summarized in this manuscript. A metabolic scheme for R788/R406 in humans, including a unique contribution of anaerobic gut bacteria to the overall metabolism, is proposed.
This article has not been copyedited and formatted. The final version may differ from this version. protocol. Participants were housed in the clinical unit until the end of the study (up to 8 days). The target dose of 14 C-R788 (150 mg, 100 µCi) was administered orally as a solution in 0.01 N citrate buffer (pH 6) using a syringe. Subjects were fasted for 10 hrs before R788 administration.
Blood samples were obtained pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 32, 48, 72, 96, 120, 144 , and 168 hrs post-dose, and then at 24-hr intervals until discharged.
Blood samples were collected into lavender top Vacutainer ® tubes containing K 2 EDTA and were kept on ice until plasma was prepared by centrifugation. Urine samples were Radioactivity profiles of urine, plasma and feces were performed using a HewlettPackard HP1000 series HPLC system equipped with a Waters Nova-Pak C18, 3.9 x 300 mm column (4 μm) and a Phenomenex C18, 3 x 4mm guard column. Columns were This article has not been copyedited and formatted. The final version may differ from this version. Selected samples of human plasma, urine, and feces were analyzed by LC/MS using a Shimadzu/ Prominence HPLC system consisting of SIL-20AC HT (10°C) autosampler, a CBM-20A controller, two LC-20AD pumps, and a CTO-20AC column oven (30°C).
Mass spectrometry was performed using a Thermo Fisher Scientific LTQ Orbitrap XL with electrospray ionization in the positive mode and Xcalibur 2.0 software. Separations were performed using a Waters Nova-Pak C18 column (3.9 x 300 mm, 4 µm) equipped with a Phenomenex C18 guard column (3 x 4 mm). Mobile phase A was 20 mM ammonium acetate and mobile phase B was acetonitrile. Flow rate was 1 mL/min. Initial conditions were 97% mobile phase A and the percentage of mobile phase B was increased linearly to 20% (20 mins), 24% (30 mins), 55% (38 min), and 80% (43 min) where it was held for 5 mins.
Purification and NMR analysis of major fecal metabolite
Twenty grams of human feces were mixed with an equal volume of water. Twice the volume of MTBE was added for liquid-liquid extraction (LLE). After 15 minutes of shaking, the mixture was centrifuged at 750 rpm for 5 minutes in a Beckman Allegra 6
This article has not been copyedited and formatted. The final version may differ from this version. with 5% acetonitrile and 10 mM ammonium acetate. Solvent B was 100% acetonitrile.
The isocratic method was run at 30% B. An Alltima C8 HPLC column (100 x 4.6 mm)
was used with flow rate of 1.0 mL/minute. The elution time for this metabolite was approximately 6 minutes. The collected fractions were dried down in the TurboVap evaporator and then resuspended in deuterated DMSO for NMR analysis. NMR analysis was run on a Varian Unity-300 NMR instrument. Due to the low amount of purified metabolite, the 1 H signal was collected for 3 days.
In vitro fecal incubation studies
Human fecal incubations were performed using a sterile BHI media (3.7 g /100 mL water) containing 5 mg L-cysteine /100 mL. Under aseptic conditions, 2.8 mL of the BHI media was added to a 6-well flat bottom plate (Costar 3516). R788 (100 μ M), R406 (100 
Results
In vitro metabolism
R788 was completely hydrolyzed to R406 by human intestinal microsomes within 15 mins (Figure 1 ). Complete hydrolysis to R406 was also achieved with alkaline phosphatase (not shown). With human hepatic microsomes and NADPH, a timedependent decrease in the R406 peak area was observed (T 1/2 24 mins). One major metabolite of R406 was observed by UV detection (Figure 2 ), and the protonated molecular ion of this peak (m/z 457) was 14 mass units less than R406. Based on coelution with an authentic standard, the metabolite was identified as the para Odemethylated product of R406 (R529). A smaller metabolite peak, representing the meta-O-demethylated metabolite (RT 35.78 min) was also observed in the microsomal studies.
Among the P450 inhibitors tested, ketoconazole was the only inhibitor that markedly (>90 %) reduced the formation of this metabolite. In addition, expressed CYP3A4 metabolized R406 to the greatest extent of any of the expressed isoforms examined. No appreciable loss of R406 peak area was observed following incubation with human hepatic microsomes and UDPGA. However, three distinct direct glucuronide conjugates of R406 could be observed by LC/MS (m/z 647) ( Figure 3 ).
Plasma radioactivity time course
The time course of plasma radioactivity in subjects who received a single oral dose of 14 C-R788 is shown in Figure 4 . Peak plasma radioactivity levels were observed at 1 hr after dosing in all individuals and steadily declined thereafter. Cmax for plasma This article has not been copyedited and formatted. The final version may differ from this version. 16 radioactivity levels ranged from 1770 to 2630 dpm/mL, while the plasma half-life ranged from 10.8 to 15.7 hrs. Subject 4 had the shortest plasma half life and the lowest plasma radioactivity exposure (10493 dpm*hr/mL) of all of the individuals in the study. Subject 2 had the longest half-live and the highest exposure (25343 dpm*hr/mL) of all of the subjects.
Plasma metabolites
The major peak observed in plasma at all time points was identified by LC/MS as R406, 
Profile of metabolites in urine and feces
Overall mean recovery of radioactivity from the human subjects was 99.3%. The majority of the dose (80%) was recovered in feces within 96 hrs, while urinary recovery (19.3%) was nearly complete within 72 hrs (Table 1) Two major radioactive peaks were observed in the 0 to 120 hr pooled feces from all subjects, but the relative amount of each of these peaks varied between individuals ( Figure 7) . Subject 4 had a greater proportion (11.6 to 1) of the earlier (35 min) eluting radioactive peak, while subject 2 had a greater proportion (5.5 to 1) of the later eluting radioactive peak (40 min). Three of the additional subjects had a greater proportion (1.7-3.9 to 1) of the later eluting peak, while the remaining subject had more (1.9 to 1) of the earlier eluting peak. The later eluting peak was identified by LC/MS as R406 (m/z 471).
The protonated molecular ion of the earlier eluting peak was observed at m/z 413, which was 58 daltons lower than R406. to show a coupling constant at least >7 Hz. The mass spectrum of the chemically synthesized 3,5-benzene diol metabolite was similar to that of the purified metabolite ( Figure 9 ). Therefore, based on the NMR data, the HPLC co-elution with an authentic chemically synthesized standard (data not shown) and the MS/MS data the fecal metabolite was identified as the 3,5-benzene diol metabolite of R406.
Formation of fecal metabolite in vitro
The unusual 3,5-benzene diol metabolite of R406 was only observed in feces, and therefore the role for gut microflora in the formation of this metabolite was examined.
R406, R529, R788 and the N-glucuronide of R406 were incubated with a human fecal sample under anaerobic conditions to determine if any of these compounds could be converted to the 3,5-benzene diol metabolite. After a 36 hr incubation, the only compound that was converted to the 3,5-benzene diol metabolite was R529 (Figure 10 ).
R406 was stable under these incubation conditions, while R788 and the lactam Nglucuronide of R406 were both converted to R406.
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Discussion.
Because of its poor pharmaceutical properties, R406 is orally administered as the methylene phosphate prodrug R788. This oral prodrug was designed to be cleaved to R406 by alkaline phosphatase(s) that are present on the apical brush border membranes of the intestinal enterocytes (Fleisher et al., 1985) , after which the more hydrophobic R406 would be readily absorbed. The R788 prodrug appears to perform as designed, as only low levels of R788 were observed in plasma of the human subjects. Moreover, drugrelated material was rapidly absorbed and R406 was the major radioactive peak in plasma at all time points. Although R406 was extensively metabolized prior to elimination, only low levels of circulating R406 metabolites were observed in plasma, indicating the rapid clearance of these metabolites. The plasma metabolites were identified as the glucuronide and sulfate conjugates of the para-O-demethylated metabolite (R529) and direct N-glucuronides of R406. Overall, these metabolites represented less than 3% of total radioactivity in plasma.
The substrates that undergo microsomal glucuronidation are reported in the high µM range (Williams et al., 2004) . However, other studies using hepatic microsomes have also underestimated the extent of glucuronidation in vivo (Mistry and Houston, 1987; Miners et al., 2004) , and it had been suggested that microsomes are not a useful model for predicting the clearance of drugs that undergo glucuronidation (Engtrakul et al., 2005) .
The majority of radioactivity (80%) was eliminated in feces and two major radioactive peaks were observed. One of these radioactive peaks was R406, which may have resulted either from the hydrolysis of unabsorbed R788 or from the hydrolysis of the R406 Nglucuronide secreted into bile, as both of these compounds were shown to be converted to R406 following incubation with human feces. The other major fecal radioactive peak was identified as the 3,5-benzene diol metabolite of R406. This unique metabolite was only present in feces, and was conceivably formed by the removal of the 3 methoxy groups of R406 and the subsequent dehydroxylation of the para hydroxyl group. A role for gut bacteria in the formation of this metabolite was examined as anaerobic gut bacteria have been shown to carry out the O-demethylation and dehydroxylation of the dietary lignans (Eeckhaut et al., 2008; Adlercreutz, 2007) . Secoisolaricirresinol (SECO) is the most widely studied plant lignan, and depends on conversion by colonic bacteria into the biologically active mammalian lignans enterodiol and enterolactone (Wang et al., 2001; Clavel et al., 2005) . Multiple strains of anaerobic bacteria are responsible for this (Heider and Fuchs, 1997) . In contrast to the aerobic environment, where the O-demethylation reactions are catalyzed by monooxygenases, in the anaerobic gut environment the O-demethylation reactions are mediated by corrinoiddependent methyl transferases with tetrahydrofolate serving as ultimate methyl acceptor (Berman and Frazer, 1992) . Following O-demethylation, the plant lignans are dehydroxylated by a reductive process by additional strains of anaerobic bacteria (Wang et al., 2001) . and that incubation of these biliary metabolites with monkey feces lead to the conversion of the R529 conjugates to the 3,5-benzene diol metabolite (Sweeny et al.) . As observed in human, the 3,5-benzene diol metabolite was also the major metabolite of R788 in the monkey feces.
The identification of the 3,5-benzene diol metabolite of R406 demonstrates a novel sequence of drug metabolism in which an O-demethylation mediated by a hepatic monooxygenase is followed by subsequent O-demethylations and dehydroxylation by anaerobic gut bacteria. These results indicate that gut bacteria are capable of modifying hepatic derived drug metabolites by pathways other than the commonly recognized reductive (Zachariah and Juchau, 1974) and hydrolytic pathways (Christopher et al., 2008) .
The fecal levels of the 3,5-benzene diol metabolite varied markedly amongst subjects.
Subject 4 had very high levels of the 3,5-benzene diol metabolite, while low levels of this metabolite were observed in Subject 2. One possible explanation for the variation could be differences in gut bacterial populations between subjects, as the activity of the gut microflora has been suggested to be a major determinant of the human lignan levels in plasma (Lampe and Chang, 2007) . However, as no intact R529 was observed in the feces from any of the subjects, the differences in the fecal 3,5-bezene diol metabolite levels probably did not reflect variations in the colonic bacterial populations. More likely, the variation in the 3,5-benzene diol levels in feces represents differences in formation of In summary, the metabolic fate of R788 was delineated in the human mass balance study (Scheme 1) and additional in vitro studies. The prodrug R788 was most likely cleaved by intestinal alkaline phosphates to R406, which was the major drug related product observed in plasma. R406 underwent both direct glucuronidation, and a CYP3A4-mediated para O-demethylation to R529. R529 was most likely conjugated by sulfation and glucuronidation, and these conjugates were secreted into bile. Following secretion into the gut these conjugates were hydrolyzed to R529, which was subsequently Odemethylated and dehydroxylated by anaerobic gut bacteria to the 3,5-benzene diol metabolite, which was the major metabolite fecal of R788 in humans. Overall, the formation of the unique 3,5-benzene diol metabolite resulted from a sequential process involving a hepatic monooxygenase and subsequent metabolism by multiple strains of anaerobic gut bacteria.
